Alopecia areata in a patient with Coronavirus disease of 2019
Alopecia areata in COVID-109
DOI:
https://doi.org/10.66344/jpad.v32i1.1837Abstract
Pandemic coronavirus disease (COVID-19) caused by coronavirus 2 (SARS-CoV-2) causes a severe acute respiratory syndrome affecting primarily the airway epithelium. With the increasing involvement of dermatologists in managing this crisis, skin symptoms are receiving more and more attention. In this case, we will describe alopecia areata in a 7-year-old girl associated with COVID-19.
References
1. Yaneva M, Demerdjieva Z, Darlenski R, et al. COVID-19 and skin: Analysis of the available data. Our Dermatol Online. 2020; 11(2):6-9.
2. Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020; 33:e13549.
3. Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19:102597.
4. Kutlu Ö, Aktaş H, İmren IG, et al. Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic. J Dermatolog Treat. 2022;33(2):1177.
5. Kasumagic-Halilovic E, Ovcina-Kurtovic N, Begovic B, et al. Interferon-gamma in patients with alopecia universalis. Our Dermatol Online. 2018;9:229-32.
6. Bulat V, Situm M, Azdajic MD, et al. Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Br J Clin Pharmacol. 2021;87:1578-81.
7. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-2.
8. Ramot Y, Marzani B, Pinto D, et al. F. IL-17 inhibition: is it the long-awaited savior for alopecia areata? Arch Dermatol Res. 2018; 310:383–90.
9. Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182:130-7.
10. Marraha F, Al Faker I, Rahmani N, et al. Summer in time of Coronavirus disease 2019: How to use hand sanitizers? Our Dermatol Online. 2020;11(Supp. 2):29-30.
11. Muzaffar F. Cutaneous Manifestations of COVID-19 in Children. J Pak Assoc Dermatol. 2021;31:93-102.
12. Holcomb ZE, Santillan MR, Morss-Walton PC, et al. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. J Am Acad Dermatol. 2020;83:1215-8.
13. Shaukat S, Butt G, Hussain I. Cutaneous manifestations of COVID-19. J Pak Assoc Dermatol. 2020;30:181-9.
14. Aşkın Ö, Özkoca D, Uzunçakmak TK, et al. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic. Dermatol Ther. 2021:e14746.
15. Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34;192-201.
16. Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment?- Authors' reply. Lancet Infect Dis. 2020;20:1013-4.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Prof., Dr
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
